Abstract

Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) is a multi-phase consortium that was formed in response to the U.S. Food and Drug Administration’s (FDA) Critical Path Initiative. The purpose of this public-private partnership is to streamline the discovery and development processes for new analgesic, anesthetic, and addiction medications. Key activities involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders—including, but not limited to, academia, FDA, and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations—with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

Mission

ACTTION serves as a public-private partnership with the FDA. Its purpose is to identify, prioritize,
sponsor, coordinate, and promote innovative activities—with a special interest in optimizing clinical trials—that will expedite the discovery and development of improved analgesic, anesthetic, and addiction treatments for the benefit of the public health. Key activities involve initiating and supporting strategic collaborations among a broad spectrum of stakeholders—including, but not limited to, academia, FDA and other government agencies, industry, professional organizations, patient advocacy groups, foundations, and philanthropic organizations—with the goals of sharing data and innovative thinking about the development of novel therapeutics. These strategic collaborations involve a wide range of research projects and other activities, for example, scientific workshops, consensus meetings, and in-depth analyses of clinical trial data to determine the effects of research methods on study assay sensitivity and efficiency.

Multiple consortia operate under the ACTTION umbrella, including:

**Consortium History**

2011: University of Rochester sponsors the Accelerating the Development of Enhanced Pain Treatments meeting in Bermuda.
2011: Inaugural Scientific Workshop is held at the FDA White Oak Campus in Maryland.
2012: Second scientific workshop is held.
2014: Third scientific workshop is held.

**Structure & Governance**

The academic founders (Robert H. Dworkin, PhD, University of Rochester; Dennis C. Turk, PhD, University of Washington) serve as the chair and vice-chair of the Executive Committee.

**Financing**

Industry participants pay a membership fee to support the management and operations of the consortium; the University of Rochester serves as a custodian of the funds. The University of Rochester relies on a quarterly budget review by the ACTTION Steering Committee as the authorization for all payments from the ACTTION industry account.
Impact/Accomplishment

As of May 2014, six ACTTION articles had been published or accepted since January 2014.

Links/Social Media Feed

Homepage http://www.acttion.org/home

Points of Contact

Robert H. Dworkin, PhD, ACTTION Director
Professor of Anesthesiology, Neurology, Oncology, and Psychiatry
Professor of Neurology in the Center for Human Experimental Therapeutics
University of Rochester School of Medicine and Dentistry
601 Elmwood Avenue, Box 604
Rochester, NY 14642
phone: (585) 275-8214
fax: (585) 276-0122
email: robert_dworkin@urmc.rochester.edu

Dennis C. Turk, PhD, ACTTION Associate Director
John and Emma Bonica Professor of Anesthesiology & Pain Research
Director, Center for Pain Research on Impact, Measurement, & Effectiveness (C-PRIME)
Editor-in-Chief, Clinical Journal of Pain
Department of Anesthesiology & Pain Medicine, Box 356540
University of Washington
Seattle, WA 98195
phone: (206) 616-2626
fax: (206) 543-2958
email: turkdc@uw.edu
Sponsors & Partners

American Academy of Neurology
American Academy of Pain Medicine
American Chronic Pain Association
American College of Rheumatology
American Pain Society
American Society of Anesthesiologists

ANNOVATION
Astellas
Chronic Pain Research Alliance
Coleggium Pharmaceutical
Depomed
Eli Lilly Co.
Europain
German Research Network on Neuropathic Pain
Horizon Pharma
International Association for the Study of Pain
Jazz Pharmaceuticals
Johnson & Johnson
Neuropathy Association
Olatec Industries LLC
Osteoarthritis Research Society International
Outcome Measures in Rheumatology
Pfizer
Purdue
Spinifex
Teva
U.S. Food and Drug Administration

Updated: 04/06/2016